English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

In ANCA-associated vasculitides (AAVs) cyclophosphamide (CYC) is part of the standard therapy regimen for severe manifestations. Rituximab (RTX) is effective in the treatment of AAVs. No data on the cumulative effect of a sequential treatment with CYC and rituximab on immunoglobulin levels in AAV are available. Such data are of great interest since both therapies can induce hypogammaglobulinemia leading to an increased risk of infections worsening the overall outcome.

journal of translational medicine

B cell depletion by Rituximab severely reduces immunoglobulin levels in patients with ANCA-associated vasculitis previously treated with cyclophosphamide